Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STANISLAV TOLKACHJOV

Allopathic & Osteopathic Physicians Dermatology

NPI
1952662868
CMS profile
618110
Location
LEWISVILLE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$9,224.64

80 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STANISLAV TOLKACHJOV

NPI 1952662868 · CMS profile ID 618110

Allopathic & Osteopathic Physicians / Dermatology

LEWISVILLE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1952662868?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STANISLAV TOLKACHJOV, NPI 1952662868, CMS profile ID 618110. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1952662868?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). STANISLAV TOLKACHJOV, NPI 1952662868, CMS profile ID 618110. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1952662868?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
STANISLAV TOLKACHJOV, NPI 1952662868, CMS profile ID 618110, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1952662868?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

80 matching records · $9,224.64 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 80 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–80 of 80.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
OptiNose US, Inc. $13.6708/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684270763 CMS
Merck Sharp & Dohme Corporation $6.7308/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695682003 CMS
Lilly USA, LLC $10.7608/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658167181 CMS
Allergan Inc. $11.3308/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671233289 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $79.8008/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684606883 CMS
AbbVie, Inc. $17.1507/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648000519 CMS
Galderma Laboratories, L.P. $12.5707/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687723251 CMS
Celgene Corporation $4.6907/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672886046 CMS
AbbVie, Inc. $125.0007/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648000529 CMS
Merck Sharp & Dohme Corporation $6.9707/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695644111 CMS
Lilly USA, LLC $13.9206/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658173621 CMS
CSL Behring $22.6706/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683884237 CMS
Merck Sharp & Dohme Corporation $6.0206/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695599499 CMS
Novartis Pharmaceuticals Corporation $24.4206/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660181921 CMS
Galderma Laboratories, L.P. $13.1806/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687723249 CMS
Merck Sharp & Dohme Corporation $8.8105/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695519979 CMS
Allergan Inc. $108.9705/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671233287 CMS
Celgene Corporation $110.9405/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672907721 CMS
AbbVie, Inc. $124.9905/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648000527 CMS
Celgene Corporation $0.7504/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672816496 CMS
Celgene Corporation $16.1104/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672817925 CMS
Celgene Corporation $2.0104/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673024845 CMS
Celgene Corporation $101.5803/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672829501 CMS
Aclaris Therapeutics, Inc. $20.0303/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700985515 CMS
Galderma Laboratories, L.P. $14.2903/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687723247 CMS
Lilly USA, LLC $97.8703/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658160501 CMS
AbbVie, Inc. $116.9103/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648000525 CMS
Novartis Pharmaceuticals Corporation $14.0203/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660181919 CMS
Lilly USA, LLC $97.6702/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658150265 CMS
Grifols Shared Services North America, Inc. $85.9301/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692580675 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $9,224.64 80
PY2020 $4,273.33 53
PY2021 $30,146.19 74
PY2022 $29,770.24 82
PY2023 $3,006.42 35
PY2024 $108,340.97 61
PY2025 $77,999.26 79

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,414.75 9
PY2025 Principal investigator $125,694.04 66
PY2022 Recipient $35,350.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

75 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,000.00 12/11/2025 Non-covered Recipient Entity
STRYDE CONSULTING LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184274841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,200.00 12/11/2025 Non-covered Recipient Entity
STRYDE CONSULTING LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184274843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 12/11/2025 Non-covered Recipient Entity
STRYDE CONSULTING LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184274845
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,259.00 12/11/2025 Non-covered Recipient Entity
STRYDE CONSULTING LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184274847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,250.00 12/11/2025 Non-covered Recipient Entity
STRYDE CONSULTING LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184274849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,431.56 11/14/2025 Non-covered Recipient Entity
STRYDE CONSULTING LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184261063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,583.36 11/07/2025 Non-covered Recipient Entity
STRYDE CONSULTING LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184258071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,431.56 10/29/2025 Non-covered Recipient Entity
STRYDE CONSULTING LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184253905
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 10/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671244
Principal investigator 1 Boehringer Ingelheim International GmbH $693.50 10/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671246
Principal investigator 1 Boehringer Ingelheim International GmbH $14.40 10/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671248
Principal investigator 1 Boehringer Ingelheim International GmbH $196.65 10/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671250
Principal investigator 1 Boehringer Ingelheim International GmbH $35.49 10/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671252
Principal investigator 1 Boehringer Ingelheim International GmbH $35.49 10/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671254
Principal investigator 1 Boehringer Ingelheim International GmbH $35.49 10/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671256
Principal investigator 1 Boehringer Ingelheim International GmbH $35.49 10/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671258
Principal investigator 1 Boehringer Ingelheim International GmbH $140.76 10/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671260
Principal investigator 1 Boehringer Ingelheim International GmbH $27.00 10/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671262
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,969.50 10/23/2025 Non-covered Recipient Entity
STRYDE CONSULTING LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184252872
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,273.00 09/24/2025 Non-covered Recipient Entity
Stryde Consulting LLC
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220814129
Principal investigator 1 Boehringer Ingelheim International GmbH $1.03 08/28/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671238
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 08/26/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671240
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 08/26/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671242
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,008.00 08/21/2025 Non-covered Recipient Entity
Stryde Consulting LLC
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220814127
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $23,875.00 07/23/2025 Non-covered Recipient Entity
Stryde Consulting LLC
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220814125
Recipient Regeneron Pharmaceuticals, Inc. $44.00 06/27/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184123528
Recipient Regeneron Pharmaceuticals, Inc. $53.60 06/27/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184123530
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 06/24/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671236
Recipient Regeneron Pharmaceuticals, Inc. $51.86 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184123516
Recipient Regeneron Pharmaceuticals, Inc. $57.46 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184123518
Recipient Regeneron Pharmaceuticals, Inc. $98.90 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184123520
Recipient Regeneron Pharmaceuticals, Inc. $103.02 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184123522
Recipient Regeneron Pharmaceuticals, Inc. $127.07 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184123524
Recipient Regeneron Pharmaceuticals, Inc. $418.88 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184123526
Principal investigator 1 Boehringer Ingelheim International GmbH $19.92 05/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671226
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 05/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671228
Principal investigator 1 Boehringer Ingelheim International GmbH $58.62 05/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671230
Principal investigator 1 Boehringer Ingelheim International GmbH $71.52 05/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671232
Principal investigator 1 Boehringer Ingelheim International GmbH $46.92 05/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671234
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $39,618.00 05/27/2025 Non-covered Recipient Entity
Stryde Consulting LLC
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220814123
Recipient Regeneron Pharmaceuticals, Inc. $459.96 05/19/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184123514
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $25.24 05/07/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220796371
Principal investigator 1 Boehringer Ingelheim International GmbH $29.76 05/01/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671214
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 04/23/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671216
Principal investigator 1 Boehringer Ingelheim International GmbH $7.20 04/23/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671218
Principal investigator 1 Boehringer Ingelheim International GmbH $87.40 04/23/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671220
Principal investigator 1 Boehringer Ingelheim International GmbH $70.38 04/23/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671222
Principal investigator 1 Boehringer Ingelheim International GmbH $12.50 04/23/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671224
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $31.11 04/15/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220796369
Principal investigator 1 Boehringer Ingelheim International GmbH $912.50 03/25/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671176
Principal investigator 1 Boehringer Ingelheim International GmbH $7.20 03/25/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671178
Principal investigator 1 Boehringer Ingelheim International GmbH $109.25 03/25/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671180
Principal investigator 1 Boehringer Ingelheim International GmbH $65.91 03/25/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671182
Principal investigator 1 Boehringer Ingelheim International GmbH $65.91 03/25/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671184
Principal investigator 1 Boehringer Ingelheim International GmbH $65.91 03/25/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671186
Principal investigator 1 Boehringer Ingelheim International GmbH $65.91 03/25/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671188
Principal investigator 1 Boehringer Ingelheim International GmbH $70.38 03/25/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671190
Principal investigator 1 Boehringer Ingelheim International GmbH $14.50 03/25/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671192
Principal investigator 1 Boehringer Ingelheim International GmbH $30.42 01/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671164
Principal investigator 1 Boehringer Ingelheim International GmbH $30.42 01/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671166
Principal investigator 1 Boehringer Ingelheim International GmbH $19.54 01/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671168
Principal investigator 1 Boehringer Ingelheim International GmbH $23.84 01/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671170
Principal investigator 1 Boehringer Ingelheim International GmbH $62.56 01/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671172
Principal investigator 1 Boehringer Ingelheim International GmbH $11.00 01/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671174
Principal investigator 1 Boehringer Ingelheim International GmbH $6.64 01/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671194
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 01/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671196
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 01/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671198
Principal investigator 1 Boehringer Ingelheim International GmbH $474.50 01/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671200
Principal investigator 1 Boehringer Ingelheim International GmbH $4.80 01/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671202
Principal investigator 1 Boehringer Ingelheim International GmbH $87.40 01/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671204
Principal investigator 1 Boehringer Ingelheim International GmbH $1.46 01/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671206
Principal investigator 1 Boehringer Ingelheim International GmbH $20.88 01/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671208
Principal investigator 1 Boehringer Ingelheim International GmbH $30.42 01/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671210
Principal investigator 1 Boehringer Ingelheim International GmbH $30.42 01/27/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671212
Principal investigator 1 Boehringer Ingelheim International GmbH $7,440.40 01/15/2025 Non-covered Recipient Entity
Epiphany Dermatology-Lewisville
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220671162